Cargando…

Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG

Cytomegalovirus (CMV) reactivation is a frequent complication after allogeneic hematopoietic cell transplantation (HCT), whose impact on clinical outcome, in particular on leukemic relapse, is controversial. We retrospectively analyzed 687 HCT recipients with acute myeloid leukemia (AML) and ciclosp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Turki, Amin T., Tsachakis-Mück, Nikolaos, Leserer, Saskia, Crivello, Pietro, Liebregts, Tobias, Betke, Luisa, Alashkar, Ferras, Leimkühler, Nils B., Trilling, Mirko, Fleischhauer, Katharina, Beelen, Dietrich W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2021
Materias:	Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753205/ https://www.ncbi.nlm.nih.gov/pubmed/34619756 http://dx.doi.org/10.1182/bloodadvances.2021005509

Ejemplares similares

P1317: TIME SERIES CLUSTERING OF T CELL SUBSETS DISSECTS HETEROGENEITY IN IMMUNE RECONSTITUTION AND SURVIVAL AMONG RECIPIENTS OF MUD-HCT WITH ATG OR PTCY
por: Turki, A., et al.
Publicado: (2022)

Time series clustering of T cell subsets dissects heterogeneity in immune reconstitution and clinical outcomes among MUD-HCT patients receiving ATG or PTCy
por: Leserer, Saskia, et al.
Publicado: (2023)

CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia
por: Akahoshi, Yu, et al.
Publicado: (2023)

Combined Analysis of Early CD4(+) T Cell Counts and CMV Serostatus May Improve CMV Risk Assessment after Allogeneic Hematopoietic Cell Transplantation
por: Leserer, Saskia, et al.
Publicado: (2021)

Emergence of human CMV-induced NKG2C(+) NK cells is associated with CD8(+) T-cell recovery after allogeneic HCT
por: van der Ploeg, Kattria, et al.
Publicado: (2023)

The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT
por: Shouval, Roni, et al.
Publicado: (2022)

Improved access to HCT with reduced racial disparities through integration with leukemia care and haploidentical donors
por: Bashey, Asad, et al.
Publicado: (2023)

Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen
por: Versluijs, A. Birgitta, et al.
Publicado: (2022)

Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT
por: Geerlinks, Ashley V., et al.
Publicado: (2023)

Cumulative incidence of subsequent malignancy after allo-HCT conditioned with or without low-dose total body irradiation
por: Nunez, Lina, et al.
Publicado: (2022)

Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
por: Menghrajani, Kamal, et al.
Publicado: (2022)

Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation
por: Ueda Oshima, Masumi, et al.
Publicado: (2023)

The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients
por: Sourisseau, Mathilde, et al.
Publicado: (2022)

Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant
por: Jimenez Jimenez, Antonio, et al.
Publicado: (2022)

Outcomes Following ATG Therapy for Chronic Lung Allograft Dysfunction
por: Kotecha, Sakhee, et al.
Publicado: (2021)

Type 1 interferon to prevent leukemia relapse after allogeneic transplantation
por: Magenau, John M., et al.
Publicado: (2021)

EASIX-1year and late mortality after allogeneic stem cell transplantation
por: Kordelas, Lambros, et al.
Publicado: (2023)

Early report on the severity of COVID‐19 in hematologic patients infected with the SARS‐CoV2 omicron variant
por: Ullrich, Fabian, et al.
Publicado: (2022)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse
por: Shapiro, Roman M., et al.
Publicado: (2023)

Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation
por: Kaloyannidis, Panayotis, et al.
Publicado: (2019)

Primary graft failure, but not relapse, may be identified by early chimerism following double cord blood unit transplantation
por: Hough, Rachael, et al.
Publicado: (2022)

T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancy
por: Horgan, Claire, et al.
Publicado: (2023)

Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning
por: Iwasaki, Makoto, et al.
Publicado: (2022)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

491. Characterizing the Association of Pre-Existing Cytomegalovirus (CMV)-specific Humoral Immunity with CMV Reactivation Risk after Hematopoietic Cell Transplantation (HCT)
por: Zamora, Danniel, et al.
Publicado: (2022)

Treatment of AML Relapse After Allo-HCT
por: Webster, Jonathan A., et al.
Publicado: (2021)

Identification of Respiratory Viral Infection in Hematopoietic Stem Cell Transplant Recipients - Impact on Non Relapse Mortality
por: Imlay-Gillespie, Louise, et al.
Publicado: (2015)

Microbiologic Diagnostic Workup of Acute Respiratory Failure with Pulmonary Infiltrates after Allogeneic Hematopoietic Stem Cell Transplantation: Findings in the Era of Molecular- and Biomarker-Based Assays
por: Wohlfarth, Philipp, et al.
Publicado: (2018)

Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy
por: Hakki, Morgan
Publicado: (2020)

91. Differential Impact of Cytomegalovirus (CMV) Donor (D) Serostatus on Rates and Kinetics of CMV Viremia among CMV Seropositive Recipients (R+) of Ex vivo T-cell Depleted (TCD) and Unmodified (CONV) Hematopoietic Cell Transplants (HCT)
por: Stern, Anat, et al.
Publicado: (2019)

2591. The Role of Neutralizing Antibodies (nAb) Against Cytomegalovirus (CMV) Epithelial Cell-entry in Patients with Self-limited (SL) CMV infection after Hematopoietic Cell Transplantation (HCT)
por: Zamora, Danniel, et al.
Publicado: (2019)

Capture and enrichment of CD34-positive haematopoietic stem and progenitor cells from blood circulation using P-selectin in an implantable device
por: Wojciechowski, Joel C, et al.
Publicado: (2008)

Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects
por: Abramowicz, Daniel, et al.
Publicado: (2008)

Risk factors for polyoma virus nephropathy
por: Prince, Olivier, et al.
Publicado: (2009)

Benefit of kidney transplantation beyond 70 years of age
por: Heldal, Kristian, et al.
Publicado: (2010)

Pancreas transplantation: differences in activity between Europe and the United States
por: Manuel González-Posada, José, et al.
Publicado: (2009)

Improvement in kidney transplantation in the Balkans after the Istanbul Declaration: where do we stand today?
por: Spasovski, Goce, et al.
Publicado: (2016)

Reciprocating living kidney donor generosity: tax credits, health insurance and an outcomes registry
por: Joshi, Shivam, et al.
Publicado: (2016)

A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants
por: Jardine, Laura, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_svqjkhhf80r4ag22f3q1jpp6of